Received Nov 28, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | UNK | — |
subsequently developed Shingles in her eye.; This serious case was reported by a consumer via call center representative and described the occurrence of ophthalmic herpes zoster in a 81-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis. On an unknown date, the patient received the 1st dose of Shingrix. On an unknown date, an unknown time after receiving Shingrix, the patient experienced ophthalmic herpes zoster (Verbatim: subsequently developed Shingles in her eye.) (serious criteria GSK medically significant). The patient was treated with valaciclovir (Valacyclovir). The outcome of the ophthalmic herpes zoster was unknown. It was unknown if the reporter considered the ophthalmic herpes zoster to be related to Shingrix. The company considered the ophthalmic herpes zoster to be unrelated to Shingrix. Linked case(s) involving the same patient: US2025AMR153297 Additional Information: GSK receipt date: 25-NOV-2025 The patient states she received a dose shingles vaccine (believes it was Shingrix) several years ago, then subsequently developed Shingles in her eye. She was told she could not get the next vaccine for a while. The batch number was not provided and a request for this information has been made. For tolerance of 2nd dose of Shingrix, refer case US2025AMR153297.; Sender's Comments: A case of Ophthalmic herpes zoster, unknown time after receiving 1st dose of Shingrix, in a 81-year-old female patient. Based on the available information a?possible causality that the event was caused by the GSK product cannot be ascertained. Further follow up information has been sought. US-GSK-US2025AMR153297:Same Patient